Jeffrey Maxwell Holzbeierlein MD, FACS

Dr. Jeffrey Holzbeierlein is the William L. Valk Professor and the Chair of the Department of Urology for The University of Kansas Health System. He was raised in Edmond, Oklahoma and received his undergraduate degree from Vanderbilt University and his medical degree from the University of Oklahoma. He joined the faculty at the University of Kansas after completing his internship and residency at Vanderbilt University and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center, in New York.

Dr. Holzbeierlein is the current President of the Society of Urologic Oncology, a past-President of the South Central Section of the American Urological Association, the past Secretary of the SUO and the past Chair of the Fellowship Committee and serves on the Executive Board of the SUO. For this work, he received the SUO Distinguished Service Award, in 2013. He has served on the American Board of Urology Oncology Knowledge Assessment Examination Committee and is a past Assistant Editor for the Journal of Urology. He currently is a member of the Oral Boards Committee for the American Board of Urology and a past member of the written exam committee. He has served on numerous AUA Committees, including the Practice Guidelines Committee and the Public Media Committee, and he has completed the AUA Leadership Program. He has served on the Steering Committee for GU ASCO and was the Program Chair. Dr. Holzbeierlein is also the past Chair and founding member of the Young Urologic Oncologists Section of the Society of Urologic Oncology. He is a reviewer for the Journal of Urology, Cancer, and Urologic Oncology. He has also been awarded the Resident Mentoring Award for faculty at the University of Kansas Hospital.

Dr. Holzbeierlein has published numerous peer-reviewed journal articles, and has numerous presentation and abstracts in journals and textbooks dealing with urologic oncology. He has been an annual lecturer for an AUA Course focusing on the Management of High Risk Bladder Cancer that was selected as one of the “best courses” at the AUA. He has intramural and extramural grant support including a co-investigator on an R01, and is the principal investigator on a SWOG trial.

Dr. Holzbeierlein specializes in the treatment of genitourinary malignancies including bladder, kidney, testicular, and penile cancers. His research interest includes the Hsp90 inhibitors in bladder cancer and clinically decreasing the morbidity associated with cystectomy. He lives in Kansas City with his wife Jill, and their four children.